English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
When a patient has a cancerous part of their intestine surgically removed, the intestinal tract must be reconnected. While the surgically reconnected intestinal tract is healing, patients typically require a stoma, also known as an ostomy, which is a surgical opening on their abdomen that connects to their digestive tract. The stoma diverts digestive waste into an ostomy bag outside the abdomen and keeps it away from the site of reconnection. The ostomy must be reversed when it is no longer needed, which requires additional surgery and recovery time for the patient.
Created by Colospan Ltd., the CG-100 device is a silicone sheath that is introduced into the intestinal tract through the rectum, no surgery required, and covers the site where the intestinal tract has been reconnected. This sheath aims to prevent or reduce the contact of fecal material with the site of reconnection, avoiding the need for a stoma. After 10 days, when the risk for leakage is reduced, the sheath is removed without any additional surgery.
“One of the most serious complications that can happen after part of the gastrointestinal tract is surgically removed is a leak at the site of the resection,” said Craig Reickert, M.D., division head of Colon and Rectal Surgery at Henry Ford Cancer Institute. “While an ostomy procedure can reduce the risk of this type of leak, it is invasive and can be challenging for the patient to live with. One of the greatest potential benefits of this device is that it not only reduces the need for a stoma, it also does not require additional surgery to implant or remove.”
The first CG-100 procedure, which was performed at Henry Ford Hospital by colon and rectal surgeon Surya Nalamati, M.D., is part of a Food and Drug Administration Investigational Device Exemption clinical trial that is comparing the CG-100 device to a diverting stoma, the current standard of care treatment for colorectal surgery. Henry Ford is the only site in Michigan, and one of just 12 sites nationwide, currently enrolling colorectal cancer patients in this clinical trial.
The CG-100 clinical trial is multi-center and randomized, so patients who meet study requirements and agree to enter the study are randomized to either be treated with the CG-100 intraluminal bypass device or to receive a diverting stoma. The patient’s care team will continue to follow up with them for up to 39 weeks after surgery.
According to the Centers for Disease Control and Prevention, in 2017 – the latest year for which incidence data are available – 141,425 new cases of colorectal cancer were reported in the United States, and 52,547 people in the U.S. died of this cancer. While an ostomy procedure can be lifesaving for colorectal cancer patients, it also carries with it risks of complications, such as incisional hernia, surgical site infection and anastomotic stenosis.
To learn more about colorectal cancer treatment at Henry Ford Cancer Institute or to request an appointment at with a colorectal cancer specialist, visit henryford.com/services/colon-rectal-cancer.
###
About Henry Ford Health System:
Founded in 1915 by Henry Ford himself, Henry Ford Health System is a non-profit, integrated health system committed to improving people’s lives through excellence in the science and art of healthcare and healing. Henry Ford Health System consists of six hospitals including Henry Ford Hospital in Detroit; Henry Ford Macomb Hospitals; Henry Ford Wyandotte Hospital; Henry Ford West Bloomfield Hospital; Henry Ford Allegiance in Jackson, MI; and Henry Ford Kingswood Hospital – an inpatient psychiatric hospital.
Henry Ford Health System also includes Henry Ford Medical Group; Henry Ford Physician Network; more than 250 outpatient facilities; Henry Ford Pharmacy; Henry Ford OptimEyes; and other healthcare services. Our not-for-profit health plan, Health Alliance Plan (HAP) provides health coverage for more than 540,000 people.
As one of the nation’s leading academic medical centers, Henry Ford Health System trains more than 3,000 medical students, residents, and fellows annually in more than 50 accredited programs, and has trained nearly 40% of the state’s physicians. Our dedication to education and research is supported by nearly $100 million in annual grants from the National Institutes of Health and other public and private foundations.
Henry Ford Health System employs more than 33,000 people, including more than 1,600 physicians, more than 6,600 nurses and 5,000 allied health professionals.
